Tagged Articles

low bone mineral density 1 articles

Updated labels of Invokana, Invokamet include bone fracture, fall warnings

The Food and Drug Administration (FDA) has approved updated safety labels for the type 2 diabetes drugs Invokana and Invokamet that include stronger warnings regarding bone fracture risk, especially among people with decreased bone mineral density. The new warnings are listed under the WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS sections of the drug’s label. Invokana and Invokamet contain the active drug ingredient canaliflozin, and were¬†approved by the FDA in 2013 and 2014, respectively. Invokamet also includes the diabetes drug metformin. The drugs are in a class of type 2 diabetes medications known as SGLT2 inhibitors. Other drugs in this class ... Read More